Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study
This is the first study to provide scientific support for BXCL501's potential to treat PTSD and comorbid AUD.
Authors
- Ismene L. Petrakis (ORCID: https://orcid.org/0000-0002-6894-5946)
- Jenelle Newcomb
- Tracy L. Nolen (ORCID: https://orcid.org/0000-0003-2512-343X)
- Jeff Sabados
- Nathan Vandergrift (ORCID: https://orcid.org/0000-0001-9994-5466)
- Shawn Hirsch (ORCID: https://orcid.org/0000-0001-6280-9559)
- Emily Pisani
- John Harrison Krystal (ORCID: https://orcid.org/0000-0001-6952-1726)
- Thomas R. Kosten (ORCID: https://orcid.org/0000-0003-1505-555X)
- Michael De Vivo
Institutions
- RTI International (US)
- Baylor College of Medicine (US)
- Yale University (US)
- VA Connecticut Healthcare System (US)
- Io Therapeutics (United States) (US)
Publication Details
- Journal
- American Journal on Addictions
- Published
- 2024-08-16
- DOI
- https://doi.org/10.1111/ajad.13637
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Army Medical Research Acquisition Activity